Background
Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody used in combination with antineoplastic agents for the treatment of metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.
Product Details
| Reactivity | Human |
| Specificity | Detects human VEGF in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Bevacizumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB019 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human VEGF |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • Neutralization: Measured by its ability to neutralize VEGF165-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 10-80 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF165. |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |